LamKap Bio

Executive Summary

LamKap Bio is a Swiss biotechnology company founded in 2021 and headquartered in Basel. The company focuses on the research, development, and manufacturing of fully human bispecific antibodies for the treatment of malignant tumors. Its proprietary κλ-body platform enables the creation of multispecific yet natural antibody formats designed to redirect the patient's own immune cells to attack cancer cells. By leveraging a natural antibody format, LamKap Bio aims to overcome limitations associated with conventional bispecific antibodies, such as immunogenicity and manufacturing challenges. The company operates in the competitive field of cancer immunotherapy, with a specific emphasis on T-cell redirection. While the company is privately held and early-stage, its Basel location positions it within a vibrant biotech ecosystem with access to talent and partnerships. As a preclinical-stage company, LamKap Bio's progress will depend on advancing its lead candidates through IND-enabling studies and into clinical trials.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Candidate40% success
• Q2 2026Presentation of Preclinical Data at Major Conference70% success
• H2 2026Partnership or Licensing Deal for Platform Technology30% success